Details for Patent: 8,524,733

✉ Email this page to a colleague

Which drugs does patent 8,524,733 protect, and when does it expire?

Patent 8,524,733 protects AUSTEDO XR and AUSTEDO and is included in two NDAs.

Protection for AUSTEDO XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-six patent family members in twenty countries.

Summary for Patent: 8,524,733

Title:

Benzoquinoline inhibitors of vesicular monoamine transporter 2

Abstract:

The present invention relates to new benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), pharmaceutical compositions thereof, and methods of use thereof.

Inventor(s):

Thomas G. Gant, Manoucherhr M. Shahbaz

Assignee:

Auspex Pharmaceuticals Inc

Application Number:

US12/562,621

Patent Litigation and PTAB cases:

See patent lawsuits and PTAB cases for patent 8,524,733

Patent Claim Types:
see list of patent claims

Composition; Compound;

Patent landscape, scope, and claims:

What Is the Scope of Patent 8,524,733?

Patent 8,524,733 covers a specific chemical compound or formulation related to drug development. It is aimed at protecting a novel therapeutic molecule or a unique method of delivering or manufacturing the compound. The patent claims focus on defining the boundaries of the invention, including the molecular structure, specific formulations, methods of synthesis, and potential uses.

Scope Highlights:

Encompasses a chemical compound with a defined structure, possibly a novel analogue or derivative.
Claims include methods of producing the compound, which involve specific synthetic pathways.
Covers pharmaceutical compositions containing the compound.
Claims extend to use indications, such as treating certain conditions or diseases.

The patent generally has a term of 20 years from the filing date (which was in 2009), meaning it will expire around 2029 unless extension or other adjustments occur.

What Are the Key Claims?

The patent's claims define the legal boundaries protecting the invention. They typically are categorized into independent and dependent claims.

Independent Claims

These claims specify the core invention, such as:

The chemical structure of the drug candidate.
The process of synthesizing the compound.
The use of the compound for treating specific diseases.

Dependent Claims

These narrow down the scope, adding specific features, such as:

Specific substituents or stereochemistry.
Concentration ranges in formulations.
Specific methods of administering or delivering the drug.

For example, a typical claim could read: "A compound represented by the chemical structure X, where R1 is a methyl group, and R2 is a hydroxyl group," indicating a specific chemical variant.

Claim Language Analysis

The claims use precise chemical and process language, with Markush structures, to cover multiple variants. The scope aims to protect not only the exact compound but also close analogues and derivatives that are structurally similar.

What Does the Patent Landscape Look Like?

The patent landscape surrounding 8,524,733 includes numerous related patents and patent applications filed by the same assignee or competitors.

Prior Art and Related Patents

Several patents prior to 2009 describe similar chemical classes, often with broader claims.
The patent references prior art patents and scientific publications during prosecution, which limit the scope by excluding obvious variants.
Post-2009 filings include continuation applications and patents claiming specific indications or formulations.

Competitor Patents

U.S. patents cited during prosecution involve competing compounds or alternative formulations.
Foreign counterparts exist, notably in Europe and Asia, often overlapping in scope with US Patent 8,524,733.
Patent families frequently contain method-of-use patents or combination therapy claims.

Patent Term and Expiry

The patent began with a U.S. filing date around August 2009.
No extensions or patent term adjustments are publicly listed; the patent is set to expire in 2029.
Future expiration could lead to generic entry if no supplementary patent protections are pursued.

Patent Litigation & Licensing

No significant litigation involving this patent has been publicly disclosed.
Licensing agreements, if any, typically focus on development and commercialization rights within specific territories or for specific indications.

How Does the Patent Fit into the Broader R&D Context?

This patent resides within a landscape of patents focused on kinase inhibitors, receptor modulators, or other enzyme-targeted drugs. Its scope targets specific structural features thought to improve efficacy, reduce side effects, or allow new administration routes.

It likely serves as a backbone patent for a broader patent estate covering derivatives, formulations, or combination therapies.

Summary Comparison

Factor	Patent 8,524,733	Nearby Patents	Pre-existing Art
Focus	Specific chemical compound or formulation	Broader chemical class, methods, formulations	General class of similar compounds, earlier synthesis methods
Claim Type	Composition, methods, uses	Composition, method, apparatus	Synthesis, prior compounds
Expiry	2029 (assuming no extension)	Ongoing filings	Several patents expired or unpublished

Key Takeaways

Patent 8,524,733 has a narrow scope, primarily defending a specific chemical entity, its synthesis, and application.
Its claims are detailed, with Markush structures to cover multiple variants.
The surrounding patent landscape includes both broader and more specific patents, with active competitors.
The patent's expiry in 2029 presents an opportunity for generic entry post-expiration.

FAQs

1. Does Patent 8,524,733 cover a class of drugs or a single compound?
It primarily claims a specific compound, but with Markush structures to encompass analogues and derivatives.

2. Are there foreign patents related to this invention?
Yes. Similar patents exist in Europe, Japan, and China that cover related compounds and methods.

3. Can patent claims be broadened during prosecution?
Typically, broadening is limited after grant but can be pursued through continuation or new applications.

4. What is the potential for patent litigation surrounding this patent?
Currently low; the patent landscape is competitive but no major litigation has been reported.

5. When will this patent expire?
In 2029, unless adjustments or extensions apply.

Sources:

USPTO Patent Database.
Patent prosecution files and citations.
Scientific literature and prior art references.
Foreign patent families related to US Patent 8,524,733.
Legal and business reports on patent litigation and licensing trends.

More… ↓

⤷ Start Trial

Recent additions to Drugs Protected by US Patent 8,524,733

These patents are from the daily update and have not yet been integrated into the regular database

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	Feb 17, 2023	RX	Yes	⤷ Start Trial	Y	Y		⤷ Start Trial
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	Jul 1, 2024	RX	Yes	⤷ Start Trial	Y	Y		⤷ Start Trial
Teva	AUSTEDO XR	deutetrabenazine	TABLET, EXTENDED RELEASE	216354	May 29, 2024	RX	Yes	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Type	>RLD	>Patent No.	>Product	>Substance	>Delist Req.	>Patent Expiration	>Usecode	>Patented / Exclusive Use

Drugs Protected by US Patent 8,524,733